AstraZeneca’s trial flop raises bigger questions around its pipeline
AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major financial impact on the company. Most analysts estimate the trial miss wiped just 2-4% from their valuation models. Yet the shares lost roughly twice that in a single session, suggesting the market reaction reflected more than just the loss of one drug,…